STX is preparing to launch prescription iron replacement treatment Accrufer in the US, a market estimated to be worth US$1.2bn pa, the largest global market for iron replacement treatment. A self-launch can provide STX with the lion’s share of projected profits, peak sales estimate of up to US$400m
12 Mar 2021
Shield Therapeutics : US Opportunity Awaits
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Shield Therapeutics : US Opportunity Awaits
Shield Therapeutics Plc (STX:LON) | 1.4 0 0.0% | Mkt Cap: 11.1m
- Published:
12 Mar 2021 -
Author:
Emma Ulker -
Pages:
11
STX is preparing to launch prescription iron replacement treatment Accrufer in the US, a market estimated to be worth US$1.2bn pa, the largest global market for iron replacement treatment. A self-launch can provide STX with the lion’s share of projected profits, peak sales estimate of up to US$400m